Affiliations
AffiliationsItem in Clipboard
The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysisZachary J Ward et al. Lancet Oncol. 2020 Aug.
. 2020 Aug;21(8):1089-1098. doi: 10.1016/S1470-2045(20)30316-8. Authors Zachary J Ward 1 , Surbhi Grover 2 , Andrew M Scott 3 , Sungmin Woo 4 , Dina H Salama 5 , Elizabeth C Jones 6 , Tarek El-Diasty 7 , Bradley R Pieters 8 , Edward L Trimble 9 , H Alberto Vargas 4 , Hedvig Hricak 4 , Rifat Atun 10 AffiliationsItem in Clipboard
AbstractBackground: Cervical cancer is the fourth most common cancer among women worldwide, causing more than 300 000 deaths globally each year. In addition to screening and prevention, effective cancer treatment is needed to reduce cervical cancer mortality. We discuss the role of imaging in cervical cancer management and estimate the potential survival effect of scaling up imaging in several different contexts.
Methods: Using a previously developed microsimulation model of global cancer survival, we estimated stage-specific cervical cancer 5-year net survival in 200 countries and territories. We evaluated the potential survival effect of scaling up treatment (chemotherapy, surgery, radiotherapy, and targeted therapy), and imaging modalities (ultrasound, x-ray, CT, MRI, PET, and single photon emission CT [SPECT]) to the mean level of high-income countries, both individually and in combination.
Findings: We estimate global cervical cancer 5-year net survival as 42·1% (95% uncertainty interval [UI] 33·8-48·5). Among individual imaging modalities, expanding MRI would yield the largest 5-year survival gains globally (data are absolute percentage point increase in survival 0·6, 95% UI 0·1-2·1), scaling up ultrasound would yield the largest gains in low-income countries (0·5, 0·0-3·7), expanding CT and x-ray would have the greatest effect in Latin America (0·8, 0·0-3·4) and Oceania (0·4, 0·0-3·2), and expanding PET would yield the largest gains in high-income countries (0·2, 0·0-0·8). Scaling up SPECT did not show major changes in any region. Among individual treatment modalities, scaling up radiotherapy would yield the largest absolute percentage point gains in low-income countries (5·2, 0·3-13·5), and expanding surgery would have the largest effect in lower-middle-income countries (7·4, 0·3-21·1) and upper-middle-income countries (0·8, 0·0-2·9). Estimated survival gains in high-income countries were very modest. However, the gains from expanding any single treatment or imaging modality individually were small across all income levels and geographical settings. Scaling up all treatment modalities could improve global 5-year net survival to 52·4% (95% UI 44·6-62·0). In addition to expanding treatment, improving quality of care could raise survival to 57·5% (51·2-63·5), and the cumulative effect of scaling up all imaging modalities together with expanded treatment and quality of care could improve 5-year net survival for cervical cancer to 62·5% (57·7-67·8).
Interpretation: Comprehensive scale-up of treatment, imaging, and quality of care could substantially improve global cervical cancer 5-year net survival, with quality of care and imaging improvements each contributing about 25% of the total potential gains. These findings suggest that a narrow focus on the availability of treatment modalities could forgo substantial survival gains. Investments in imaging equipment, personnel, and quality of care efforts will also be needed to successfully scale up cervical cancer treatment worldwide.
Funding: Harvard T H Chan School of Public Health and National Cancer Institute.
Copyright © 2020 Elsevier Ltd. All rights reserved.
FiguresFigure 1:
Expert opinion consensus of impact…
Figure 1:
Expert opinion consensus of impact of treatment and imaging modalities on 5-year cervical…
Figure 1:Expert opinion consensus of impact of treatment and imaging modalities on 5-year cervical cancer net survival given initial stage at diagnosis
Figure 2
Estimated 5-year cervical cancer net…
Figure 2
Estimated 5-year cervical cancer net survival by country
Figure 2Estimated 5-year cervical cancer net survival by country
Figure 3
Estimated 5-year cervical cancer net…
Figure 3
Estimated 5-year cervical cancer net survival with cumulative scale-up of treatment and imaging…
Figure 3Estimated 5-year cervical cancer net survival with cumulative scale-up of treatment and imaging (A) By income group. (B) By geographical region. Shaded regions indicate 95% UI. Dashed vertical line indicates the point at which imaging scale-up begins to be added to the cumulative scale-up policices. UI=uncertainty interval. SPECT=single photon emission CT.
Similar articlesWard ZJ, Scott AM, Hricak H, Abdel-Wahab M, Paez D, Lette MM, Vargas HA, Kingham TP, Atun R. Ward ZJ, et al. Lancet Oncol. 2020 Aug;21(8):1077-1088. doi: 10.1016/S1470-2045(20)30317-X. Lancet Oncol. 2020. PMID: 32758462 Free PMC article.
Ward ZJ, Atun R, Hricak H, Asante K, McGinty G, Sutton EJ, Norton L, Scott AM, Shulman LN. Ward ZJ, et al. Lancet Oncol. 2021 Sep;22(9):1301-1311. doi: 10.1016/S1470-2045(21)00403-4. Epub 2021 Aug 17. Lancet Oncol. 2021. PMID: 34416159 Free PMC article.
Ward ZJ, Scott AM, Hricak H, Atun R. Ward ZJ, et al. Lancet Oncol. 2021 Mar;22(3):341-350. doi: 10.1016/S1470-2045(20)30750-6. Lancet Oncol. 2021. PMID: 33662286 Free PMC article.
Cubie HA, Campbell C. Cubie HA, et al. Womens Health (Lond). 2020 Jan-Dec;16:1745506520914804. doi: 10.1177/1745506520914804. Womens Health (Lond). 2020. PMID: 32364058 Free PMC article. Review.
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Forouzanfar MH, et al. Lancet. 2011 Oct 22;378(9801):1461-84. doi: 10.1016/S0140-6736(11)61351-2. Epub 2011 Sep 14. Lancet. 2011. PMID: 21924486 Review.
Cao Y. Cao Y. J Cancer Res Clin Oncol. 2023 Aug;149(10):7471-7477. doi: 10.1007/s00432-023-04692-4. Epub 2023 Mar 24. J Cancer Res Clin Oncol. 2023. PMID: 36959342
Rajabi A, Dastmalchi N, Shokri N, Tayefeh-Gholami S, Yaghoubi SM, Safaralizadeh R. Rajabi A, et al. Rep Biochem Mol Biol. 2023 Apr;12(1):120-126. doi: 10.52547/rbmb.12.1.120. Rep Biochem Mol Biol. 2023. PMID: 37724154 Free PMC article.
Matos AGM, Silva GEB, Barbosa EDS, de Andrade MS, Santos Lages J, Corrêa RDGCF, Oliveira AGC, Teixeira EB, da Silva MGOP, da Fonseca SSS, Teixeira-Júnior AAL, Alves MS, Alencar Junior AM, Khayat AS, Pinho JD. Matos AGM, et al. Front Genet. 2024 May 27;15:1287869. doi: 10.3389/fgene.2024.1287869. eCollection 2024. Front Genet. 2024. PMID: 38859935 Free PMC article.
Yang LL, Zhang XK, Cao Y, Shi LY, Xie SY, Yang YJ, Wu SJ, Sun HZ, Tang XJ, Yuan DL, Zhang D, Xu XF, Li Q, Ying XY. Yang LL, et al. Med Oncol. 2024 Oct 14;41(11):273. doi: 10.1007/s12032-024-02315-7. Med Oncol. 2024. PMID: 39400626
Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM. Hricak H, et al. Lancet Oncol. 2021 Apr;22(4):e136-e172. doi: 10.1016/S1470-2045(20)30751-8. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676609 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3